Stockscreener 앱 받기
0.6491
4.11%
0.0256
시간 외 거래:
.65
0.0009
+0.14%
Adaptimmune Therapeutics Plc Adr 주식(ADAP)의 최신 뉴스
AST SpaceMobile Inc Still Hasn’t Convinced Analysts? - Stocks Register
These Numbers Show Just How Powerful Standard Lithium Ltd (AMEX: SLI) Stock Is - Stocks Register
What Did We Note About Insider Trading At Lithium Americas Corp (NewCo) (NYSE: LAC)? - Stocks Register
Workhorse Group Inc (NASDAQ: WKHS) Could Pass $3.5 In One Year Stock Forecast - Stocks Register
Barnes & Noble Education Inc (NYSE: BNED) -10.53% Decline Turns Investors Away - Stocks Register
Applied Digital Corporation (NASDAQ: APLD) Could Pass $10 In One Year Stock Forecast - Stocks Register
Asana Inc (NYSE: ASAN) Up 15.57% This Year: What Is Going To Happen Next - Stocks Register
Adaptimmune's SWOT analysis: TCR-T pioneer faces challenges in stock outlook - Investing.com
Adaptimmune's SWOT analysis: TCR-T therapy pioneer faces challenges post-FDA nod - Investing.com
Royal Dutch Shell Plc ADR (SHEL-N) QuotePress Release - The Globe and Mail
Mizuho lowers Adaptimmune price target by 50%, citing pipeline shifts and cost cuts - Investing.com
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register
Analysts Predict Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) To Loss -577.97% From Current Levels. - Stocks Register
Earnings call: Adaptimmune outlines new strategy amid Tecelra launch By Investing.com - Investing.com South Africa
Adaptimmune stock holds Buy rating with lower target amid Q3 revenue outperformance - Investing.com
ADAPAdaptimmune Therapeutics plc American Depositary Shares Latest Stock News & Market Updates - StockTitan
Adaptimmune faces Nasdaq delisting over share price - Investing.com India
NVIDIA Corp (NVDA): Be Patient, You Will Learn - Stocks Register
Investing in HUYA Inc ADR (HUYA): What You Must Know - Knox Daily
Checking in on Blackstone Inc (BX) after recent insiders movement - Knox Daily
Ready to Jump After Recent Trade: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Ratio Examination: Adaptimmune Therapeutics Plc ADR (ADAP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Was anything negative for Adaptimmune Therapeutics Plc ADR (ADAP) stock last session? - US Post News
Chief Commercial Officer Piccina Cintia sale 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP] - Knox Daily
The Significance of Moving Averages in Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance - The InvestChronicle
Technical analysis of Adaptimmune Therapeutics Plc ADR (ADAP) stock chart patterns - US Post News
Adaptimmune Therapeutics Plc ADR (ADAP)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
A significant driver of top-line growth: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Analysts review Adaptimmune Therapeutics Plc ADR’s rating - Knox Daily
How should investors view Adaptimmune Therapeutics Plc ADR (ADAP)? - US Post News
Recent Insider Activity Could Benefit Zentalis Pharmaceuticals Inc (ZNTL) - Knox Daily
Wall Street SWOT: Adaptimmune stock faces challenges despite FDA win - Investing.com
Stocks of Adaptimmune Therapeutics Plc ADR (ADAP) are poised to climb above their peers - SETE News
Insider Sale Alert: Gap, Inc. [GAP] – Is it Time to sell? - Knox Daily
Adaptimmune Therapeutics Plc ADR [ADAP] Piccina Cintia sells 24,531 Shares for $22814.0 - Knox Daily
Adaptimmune finalizes settlement with Genentech - Investing.com India
ADAP’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
Ratios Uncovered: Breaking Down Adaptimmune Therapeutics Plc ADR (ADAP)’s Trailing Twelve Months Metrics - The Dwinnex
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Yahoo Finance UK
Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance: Is It Undervalued or Overvalued? - The InvestChronicle
Recent Insider Activity Could Benefit Adaptimmune Therapeutics Plc ADR (ADAP) - Knox Daily
Zumiez Inc’s latest rating changes from various analysts - Knox Daily
AdaptHealth Stock Earns RS Rating Upgrade - MSN
A new trading data show Adaptimmune Therapeutics Plc ADR (ADAP) is showing positive returns. - SETE News
Predicting Adaptimmune Therapeutics Plc ADR’s (ADAP) earnings for the current quarter - US Post News
Director SIMON WILLIAM E JR acquire 45,000 shares of Douglas Emmett Inc [DEI] - Knox Daily
Buying Buzz: Noble Corp Plc [NE] 10% Owner APMH Invest A/S purchases 324,984 shares of the company - Knox Daily
There is no doubt that Adaptimmune Therapeutics Plc ADR (ADAP) ticks all the boxes. - SETE News
Analyzing Ratios: Adaptimmune Therapeutics Plc ADR (ADAP)’s Financial Story Unveiled - The Dwinnex
Adaptimmune Therapeutics Plc ADR (ADAP) stock analysis: A simple moving average approach - US Post News
A company insider recently sold 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP]. Should You Sale? - Knox Daily
EWCZ Shares Experience Decline in Value - Knox Daily
Natera Inc [NTRA] Shares Jump Approximately 97.71% Over the Year - Knox Daily
Adaptimmune Therapeutics Plc ADR’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
Premier Inc [PINC] Shares Fall -1.35 % on Thursday - Knox Daily
An analyst sees good growth prospects for Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Closing Figures: Adaptimmune Therapeutics Plc ADR (ADAP)’s Negative Finish at 1.16, Down -4.13 - The Dwinnex
Analyzing Adaptimmune Therapeutics Plc ADR (ADAP) After Recent Trading Activity - Knox Daily
Adaptimmune Therapeutics Plc ADR (ADAP) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Market Recap Check: Adaptimmune Therapeutics Plc ADR (ADAP)’s Negative Finish at 1.24, Up/Down -6.77 - The Dwinnex
Adaptimmune Therapeutics Plc ADR: Rising -35.12% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
A closer look at Adaptimmune Therapeutics Plc ADR (ADAP)’s stock price trends - US Post News
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
A better buy-in window may exist right now for Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Financial Analysis: Adaptimmune Therapeutics Plc ADR (ADAP)’s Ratios Unveil Key Insights - The Dwinnex
The Adaptimmune Therapeutics Plc ADR (ADAP) had a good session last reading, didn’t it? - US Post News
0.60%
2.24%
자본화:
|
볼륨(24시간):